Proximity-driven site-specific cyclization of phage-displayed peptides.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
24 Aug 2024
Historique:
received: 17 11 2023
accepted: 13 08 2024
medline: 26 8 2024
pubmed: 26 8 2024
entrez: 24 8 2024
Statut: epublish

Résumé

Cyclization provides a general strategy for improving the proteolytic stability, cell membrane permeability and target binding affinity of peptides. Insertion of a stable, non-reducible linker into a disulphide bond is a commonly used approach for cyclizing phage-displayed peptides. However, among the vast collection of cysteine reactive linkers available, few provide the selectivity required to target specific cysteine residues within the peptide in the phage display system, whilst sparing those on the phage capsid. Here, we report the development of a cyclopropenone-based proximity-driven chemical linker that can efficiently cyclize synthetic peptides and peptides fused to a phage-coat protein, and cyclize phage-displayed peptides in a site-specific manner, with no disruption to phage infectivity. Our cyclization strategy enables the construction of stable, highly diverse phage display libraries. These libraries can be used for the selection of high-affinity cyclic peptide binders, as exemplified through model selections on streptavidin and the therapeutic target αvβ3.

Identifiants

pubmed: 39181880
doi: 10.1038/s41467-024-51610-4
pii: 10.1038/s41467-024-51610-4
doi:

Substances chimiques

Peptide Library 0
Peptides, Cyclic 0
Streptavidin 9013-20-1
Capsid Proteins 0
Cysteine K848JZ4886
Cyclopropanes 0
Peptides 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

7308

Subventions

Organisme : RCUK | Biotechnology and Biological Sciences Research Council (BBSRC)
ID : 10046039
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : 493006134

Informations de copyright

© 2024. The Author(s).

Références

Chen, S. Y. et al. Bicyclic peptide ligands pulled out of cysteine-rich peptide libraries. J. Am. Chem. Soc. 135, 6562–6569 (2013).
doi: 10.1021/ja400461h pubmed: 23560397
Zhang, Y., Zhang, Q., Wong, C. T. T. & Li, X. C. Chemoselective peptide cyclization and bicyclization directly on unprotected peptides. J. Am. Chem. Soc. 141, 12274–12279 (2019).
doi: 10.1021/jacs.9b03623 pubmed: 31314512
Smith, G. Filamentous fusion phage – Novel expression vectors that display cloned antigens on the virion surface. Science 228, 1315–1317 (1985).
doi: 10.1126/science.4001944 pubmed: 4001944
Deyle, K., Kong, X. & Heinis, C. Phage selection of cyclic peptides for application in research and drug development. Acc. Chem. Res. 50, 1866–1874 (2017).
doi: 10.1021/acs.accounts.7b00184 pubmed: 28719188
Mclafferty, M., Kent, R., Ladner, R. & Markland, W. Bacteriophage-M-13 displaying disulfide-constrained microproteins. Gene 128, 29–36 (1993).
doi: 10.1016/0378-1119(93)90149-W pubmed: 8508957
Heinis, C., Rutherford, T., Freund, S. & Winter, G. Phage-encoded combinatorial chemical libraries based on bicyclic peptides. Nat. Chem. Biol. 5, 502–507 (2009).
doi: 10.1038/nchembio.184 pubmed: 19483697
Chen, S., Bertoldo, D., Angelini, A., Pojer, F. & Heinis, C. Peptide ligands stabilized by small molecules. Angew. Chem. Int. Ed. 126, 1628–1632 (2014).
doi: 10.1002/ange.201309459
Kather, I., Bippes, C. A. & Schmid, F. X. A stable disulfide-free gene-3-protein of phage fd generated by in vitro evolution. J. Mol. Biol. 354, 666–678 (2005).
doi: 10.1016/j.jmb.2005.09.086 pubmed: 16259997
Wang, X. S. S. et al. A genetically encoded, phage-displayed cyclic-peptide library. Angew. Chem. Int. Ed. 58, 15904–15909 (2019).
doi: 10.1002/anie.201908713
Simonetti, L. & Ivarsson, Y. Genetically encoded cyclic peptide phage display libraries. ACS Cent. Sci. 6, 336–338 (2020).
doi: 10.1021/acscentsci.0c00087 pubmed: 32232131 pmcid: 7099589
Owens, A., Iannuzzelli, J., Gu, Y. & Fasan, R. MOrPH-PhD: An integrated phage display platform for the discovery of functional genetically encoded peptide macrocycles. ACS Cent. Sci. 6, 368–381 (2020).
doi: 10.1021/acscentsci.9b00927 pubmed: 32232137 pmcid: 7099587
Istrate, A. et al. Platform for orthogonal N-cysteine-specific protein modification enabled by cyclopropenone reagents. J. Am. Chem. Soc. 144, 10396–10406 (2022).
doi: 10.1021/jacs.2c02185 pubmed: 35658467 pmcid: 9490850
Danhier, F., Le Breton, A. & Préat, V. R. RGD-based strategies to target alpha (v) beta (3) integrin in cancer therapy and diagnosis. Mol. Pharm. 9, 2961–2973 (2012).
doi: 10.1021/mp3002733 pubmed: 22967287
Dwyer, M. A., Lu, W., Dwyer, J. J. & Kossiakoff, A. A. Biosynthetic phage display: a novel protein engineering tool combining chemical and genetic diversity. Chem. Biol. 7, 263–274 (2000).
doi: 10.1016/S1074-5521(00)00102-2 pubmed: 10780926
Hampton, J. T. et al. Novel regioselective approach to cyclize phage-displayed peptides in combination with epitope-directed selection to identify a potent neutralizing macrocyclic peptide for SARS-CoV-2. ACS Chem. Biol. 17, 2911–2922 (2022).
doi: 10.1021/acschembio.2c00565 pubmed: 36174018 pmcid: 9528030
Zheng, M., Haeffner, F. & Gao, J. N-Terminal cysteine mediated backbone-side chain cyclization for chemically enhanced phage display. Chem. Sci. 13, 8349–8354 (2022).
doi: 10.1039/D2SC03241D pubmed: 35919713 pmcid: 9297441
Zheng, X. et al. Condensation of 2-((alkylthio)(aryl) methylene) malononitrile with 1, 2-aminothiol as a novel bioorthogonal reaction for site-specific protein modification and peptide cyclization. J. Am. Chem. Soc. 142, 5097–5103 (2020).
doi: 10.1021/jacs.9b11875 pubmed: 32108479
Powers, J. C., Asgian, J. L., Ekici, Ö. D. & James, K. E. Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem. Rev. 102, 4639–4750 (2002).
doi: 10.1021/cr010182v pubmed: 12475205
Thie, H., Schirrmann, T., Paschke, M., Dübel, S. & Hust, M. SRP and Sec pathway leader peptides for antibody phage display and antibody fragment production in E. coli. Nat. Biotechnol. 25, 49–54 (2008).
Li, K., Wang, W. & Gao, J. Fast and stable N‐terminal cysteine modification through thiazolidino boronate mediated Acyl transfer. Angew. Chem. Int. Ed. 59, 14246–14250 (2020).
doi: 10.1002/anie.202000837
Bechtler, C. & Lamers, C. Macrocyclization strategies for cyclic peptides and peptidomimetics. RSC Med. Chem. 12, 1325–1351 (2021).
doi: 10.1039/D1MD00083G pubmed: 34447937 pmcid: 8372203
Chasteen, L., Ayriss, J., Pavlik, P. & Bradbury, A. Eliminating helper phage from phage display. Nucleic Acids Res. 34, e145 (2006).
doi: 10.1093/nar/gkl772 pubmed: 17088290 pmcid: 1693883
Oppewal, T. R., Jansen, I. D., Hekelaar, J. & Mayer, C. A strategy to select macrocyclic peptides featuring asymmetric molecular scaffolds as cyclization units by phage display. J. Am. Chem. Soc. 144, 3644–3652 (2022).
doi: 10.1021/jacs.1c12822 pubmed: 35171585 pmcid: 8895403
Katz, B. A. Binding to protein targets of peptidic leads discovered by phage display: crystal structures of streptavidin-bound linear and cyclic peptide ligands containing the HPQ sequence. Biochemistry 34, 15421–15429 (1995).
doi: 10.1021/bi00047a005 pubmed: 7492542
Schmidt, T. G., Koepke, J., Frank, R. & Skerra, A. Molecular interaction between the Strep-tag affinity peptide and its cognate target, streptavidin. J. Mol. Biol. 255, 753–766 (1996).
doi: 10.1006/jmbi.1996.0061 pubmed: 8636976
Schmidt, T. G. et al. Development of the Twin-Strep-tag® and its application for purification of recombinant proteins from cell culture supernatants. Protein Expr. Purif. 92, 54–61 (2013).
doi: 10.1016/j.pep.2013.08.021 pubmed: 24012791
Capecchi, A., Probst, D. & Reymond, J.-L. One molecular fingerprint to rule them all: drugs, biomolecules, and the metabolome. J. Cheminform. 12, 43 (2020).
doi: 10.1186/s13321-020-00445-4 pubmed: 33431010 pmcid: 7291580
Liu, Z., Wang, F. & Chen, X. Integrin αvβ3‐targeted cancer therapy. Drug Dev. Res. 69, 329–339 (2008).
doi: 10.1002/ddr.20265 pubmed: 20628538 pmcid: 2901818

Auteurs

Libby Brown (L)

Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.
Biologics Engineering, Oncology R&D, AstraZeneca, The Discovery Centre; Cambridge Biomedical Campus, Cambridge, UK.

Aldrin V Vidal (AV)

Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.

Ana Laura Dias (AL)

Instituto de Investigação do Medicamento (iMed), Faculdade de Farmácia, Universidade de Lisboa, Lisboa, Portugal.

Tiago Rodrigues (T)

Instituto de Investigação do Medicamento (iMed), Faculdade de Farmácia, Universidade de Lisboa, Lisboa, Portugal.

Anna Sigurdardottir (A)

Biologics Engineering, Oncology R&D, AstraZeneca, The Discovery Centre; Cambridge Biomedical Campus, Cambridge, UK.

Toby Journeaux (T)

Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.

Siobhan O'Brien (S)

Biologics Engineering, Oncology R&D, AstraZeneca, The Discovery Centre; Cambridge Biomedical Campus, Cambridge, UK.

Thomas V Murray (TV)

Biologics Engineering, Oncology R&D, AstraZeneca, The Discovery Centre; Cambridge Biomedical Campus, Cambridge, UK.

Peter Ravn (P)

Biologics Engineering, Oncology R&D, AstraZeneca, The Discovery Centre; Cambridge Biomedical Campus, Cambridge, UK.
Department of Biotherapeutic Discovery, H. Lundbeck A/S, Valby, Denmark.

Monika Papworth (M)

Biologics Engineering, Oncology R&D, AstraZeneca, The Discovery Centre; Cambridge Biomedical Campus, Cambridge, UK.

Gonçalo J L Bernardes (GJL)

Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK. gb453@cam.ac.uk.
Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal. gb453@cam.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH